Background: Opioid addiction is a serious and growing global concern. Recently, herbal medicine has been popular for the treatment of opioid abusers worldwide. Unfortunately, the adulteration of herbal remedies with undeclared synthetic pharmaceuticals has been reported. In Iran, there are few reports on the adulteration of herbal remedies by synthetic pharmaceuticals sold as opioid addiction treatment. The aim of this study was to analyze herbal products used in opioid addiction treatment for the identification of synthetic pharmaceuticals as adulterants in the remedies.
Methods: Forty commonly-used handmade herbal products for the treatment of opioid addiction were collected from herbal shops in Kermanshah (western area of Iran). After organoleptic examinations, the samples were prepared and analyzed by high-performance liquid chromatography and gas chromatography-mass spectrometry for detecting probable synthetic pharmaceutical adulterants.
Results: The chromatographic analysis of the samples showed that 90% of the products had at least one undeclared pharmaceutical ingredient as an adulterant. The majority of the samples (n=19, 47.5%) had only one undeclared pharmaceutical. Diphenoxylate (n=24, 39.3%), tramadol (n=16, 26.2), methadone (n=8, 13.2%), and the combination of these drugs were reported as common adulterants. We detected the presence of buprenorphine and sildenafil as adulterating agents in the herbal formulations for the first time.
Conclusion: According to the presence of undeclared synthetic pharmaceuticals in opioid addiction herbal products, as well as their threats to public health, awareness, in this case, is necessary.
1. Blanco C, Volkow ND. Management of opioid use disorder in the USA: Present status and future directions. Lancet. 2019; 393(10182):1760-72. [DOI:10.1016/S0140-6736(18)33078-2]
2. Green J. Epidemiology of opioid abuse and addiction. Journal of Emergency Nursing. 2017; 43(2):106-13. [DOI:10.1016/j.jen.2016.09.004]
3. Marsden J, Stillwell G, James K, Shearer J, Byford S, Hellier J, et al. Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: A pragmatic, open-label, randomised controlled trial. Lancet Psychiatry. 2019; 6(5):391-402. [DOI:10.1016/S2215-0366(19)30097-5]
4. Noble F, Marie N. Management of opioid addiction with opioid substitution treatments: Beyond methadone and buprenorphine. Frontiers in Psychiatry. 2019; 9:742. [DOI: 10.3389/fpsyt.2018.00742] [PMCID] [PMID]
5. Schwartz RP, Mitchell MM, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, et al. Pharmacotherapy for opioid addiction in community corrections. International Review of Psychiatry. 2018; 6:1-19. [DOI:10.1080/09540261.2018.1524373] [PMID] [PMCID]
6. Bozinoff N, DeBeck K, Milloy MJ, Nosova E, Fairbairn N, Wood E, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada. Drug and Alcohol Dependence. 2018; 193:42-7. [DOI:10.1016/j.drugalcdep.2018.09.003] [PMID] [PMCID]
7. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Current HIV/AIDS Reports. 2010; 7(3):152-60. [DOI:10.1007/s11904-010-0048-2] [PMID] [PMCID]
8. Ward J, Rosenbaum C, Hernon C, McCurdy CR, Boyer EW. Herbal medicines for the management of opioid addiction: Safe and effective alternatives to conventional pharmacotherapy? CNS Drugs. 2011; 25(12):999-1007. [DOI:10.2165/11596830-000000000-00000] [PMID]
9. Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. Passionflower in the treatment of opiates withdrawal: A double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics. 2001; 26(5):369-73. [DOI:10.1046/j.1365-2710.2001.00366.x] [PMID]
10. Wang S, Fu P, Liu L, Wang L, Peng C, Zhang W, et al. Simultaneous determination of fifteen constituents of jitai tablet using ultra high-performance liquid chromatography coupled with triple quadrupole electrospray tandem mass spectrometry. Molecules. 2014; 19(2):1635-50. [DOI:10.3390/molecules19021635] [PMID] [PMCID]
11. Zhu W, Zhang Y, Huang Y, Lu L. Chinese herbal medicine for the treatment of drug addiction. International Review of Neurobiology. 2017; 135:279-95. [DOI:10.1016/bs.irn.2017.02.013] [PMID]
12. Liu TT, Shi J, Epstein DH, Bao YP, Lu L. A meta-analysis of Chinese herbal medicine in treatment of managed withdrawal from heroin. Cellular and Molecular Neurobiology. 2009; 29(1):17-25. [DOI:10.1007/s10571-008-9290-1.Epub 2008 Jun 27] [PMID] [PMCID]
13. de Carvalho LM, Moreira AP, Martini M, Falcão T. The illegal use of synthetic pharmaceuticals in herbal formulations: an overview of adulteration practices and analytical investigations. Forensic Science Review. 2011; 23(2):73-89. [PMID]
14. Snyman T, Stewart MJ, Grove A, Steenkamp V. Adulteration of South African traditional herbal remedies. Therapeutic Drug Monitoring. 2005; 27(1):86-9. [DOI:10.1097/00007691-200502000-00015] [PMID]
15. Lu L, Liu Y, Zhu W, Shi J, Liu Y, Ling W, et al. Traditional medicine in the treatment of drug addiction. American Journal of Drug and Alcohol Abuse. 2009; 35(1):1-11. [DOI:10.1080/00952990802455469] [PMID]
16. Ebrahimie M, Bahmani M, Shirzad H, Rafieian-Kopaei M, Saki K. A review study on the effect of Iranian herbal medicines on opioid withdrawal syndrome. Journal of Evidence-Based Complementary and Alternative Medicine. 2015; 20(4):302-9. [DOI:10.1177/2156587215577896] [PMID]
17. Skalicka-Woźniak K, Georgiev MI, Orhan IE. Adulteration of herbal sexual enhancers and slimmers: The wish for better sexual well-being and perfect body can be risky. Food and Chemical Toxicology. 2017; 108(Pt B):355-64. [DOI:10.1016/j.fct.2016.06.018] [PMID]
18. Huang YC, Lee HC, Lin YL, Lin YT, Tsai CF, Cheng HF. Identification of a new sildenafil analogue adulterant, desethylcarbodenafil, in a herbal supplement. Food additives & contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment. 2016; 33(11):1637-42. [DOI:10.1080/19440049.2016.1236402]
19. Dastjerdi AG, Akhgari M, Kamali A, Mousavi Z. Principal component analysis of synthetic adulterants in herbal supplements advertised as weight loss drugs. Complementary Therapies in Clinical Practice. 2018; 31:236-41. [DOI:10.1016/j.ctcp.2018.03.007] [PMID]
20. Saberi N, Akhgari M, Bahmanabadi L, Bazmi E, Mousavi Z. Determination of synthetic pharmaceutical adulterants in herbal weight gain supplements sold in herb shops, Tehran, Iran. Daru. 2018; 26(2):117-27. [DOI: 10.1007/s40199-018-0216-2]
21. Fakhri S, Mohammadi B, Jalili R, Hajialyani M, Bahrami G. Screening and confirmation of different synthetic adulterants in slimming products. Asian Journal of Pharmcetical and Clinical Research. 2018; 11(2):260-64. [DOI:10.22159/ajpcr.2018.v11i2.22516] [PMID] [PMCID]
22. Hafizi Fard H, Akhgari M. Analytical perspectives of chemical adulterants in herbal sexual enhancer drugs. Journal of Pharmacy and Pharmacognosy Research. 2018; 6(1):45–53.
23. Winograd RP, Presnall N, Stringfellow E, Wood C, Horn P, Duello A, et al. The case for a medication first approach to the treatment of opioid use disorder. American Journal of Drug and Alcohol Abuse. 2019; 45(4):333-40. [DOI:10.1080/00952990.2019.1605372] [PMID]
24. Arndt T, Claussen U, Güssregen B, Schröfel S, Stürzer B, Werle A, et al. Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. Forensic Science International. 2011; 208(1-3):47-52. [DOI:10.1016/j.forsciint.2010.10.025] [PMID]
25. Foroughi MH, Akhgari M, Jokar F, Mousavi Z. Identification of undeclared active pharmaceutical ingredients in counterfeit herbal medicines used as opioid substitution therapy. Australian Journal of Forensic Sciences. 2017; 49(6):720-9. [DOI:10.1080/00450618.2016.1273387]
26. Mehra A, Sarkar S, Basu D. Lomotil (diphenoxylate) dependence in India. Indian Journal of Psychology and Medeicine. 2013; 35(3):248-50. [DOI:10.4103/0253-7176.119474] [PMID] [PMCID]
27. Firoozabadi A, Mowla A, Farashbandi H, Gorman JM. Diphenoxylate hydrochloride dependency. Journal of Psychiatric Practice. 2007; 13(4):278-80. [DOI:10.1097/01.pra.0000281491.65311.c] [PMID]
28. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clinical Pharmacokinetics. 2004; 43(13):879-923. [DOI:10.2165/00003088-200443130-00004] [PMID]
29. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: Pharmacology, metabolism, and misuse. Anesthesia and Analgesia. 2017; 124(1):44-51.[DOI:10.1213/ANE.0000000000001683] [PMID]
30. Sarkar S, Lal R, Varshney M, Balhara YPS. Tramadol for maintenance in opioid dependence: A retrospective chart review. Journal of Opioid Management. 2017; 13(5):329-34.[DOI: 10.5055/jom.2017.0401] [PMID]
31. Rahimi HR, Soltaninejad K, Shadnia S. Acute tramadol poisoning and its clinical and laboratory findings. Journal of Research in Medical Sciences. 2014; 19(9):855-9. [PMID] [PMCID]
32. Memarian A, Farhidnia N, Fallahi F. Generalized tonic colonic seizure followed by loss of consciousness early after using low dose of tramadol: A case report. Anesthesiology and Pain Medicine. 2018; 8(3):e64707. [DOI:10.5812/aapm.64707] [PMID] [PMCID]
33. Rahimi Movaghar A, Khastoo G, Fekri M, Akhondzadeh S. (Treatment of addiction by medicinal herbs sellers in Tehran) [Persian]. Hakim Health System Research Journal. 2008; 11(3):11-9.
34. Xu Y, Kee CL, Ge X, Low MY, Koh HL. Isolation and characterization of a tadalafil analogue, N-cyclopentyl nortadalafil in health supplement. Journal of Pharmaceutical and Biomedical Analysis. 2016; 118:235–41. [DOI:10.1016/j.jpba.2015.08.005]
35. Chekuri V, Gerber D, Brodie A, Krishnadas R. Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment. Addictive Behaviors. 2012; 37(1):124-6. [DOI:10.1016/j.addbeh.2011.08.005] [PMID]
36. Yang L, Qian S, Liu H, Liu L, Pu C, Han P, et al. Role of tramadol in premature ejaculation: A systematic review and meta-analysis. Urologia Internationalis. 2013; 91(2):197-205. [DOI:10.1159/000348826] [PMID]
37. Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: A review. Pain Physician. 2015; 18(4):395-400. [PMID]